HACKENSACK, N.J.–(BUSINESS WIRE)–ReGen Biologics (OTC: RGBO) will conduct surgeon training on its meniscus implant prior to the Arthroscopy Association of North America’s (AANA) annual meeting, being held in San Diego April 30 – May 3.
ReGen’s Menaflex™ collagen meniscus implant is used in arthroscopic surgery to address the most common form of knee injury, a torn meniscus. The device is inserted to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus.
In the first quarter of 2009, ReGen trained 45 sports medicine surgeons on the Menaflex, who are thought leaders and many of whom are affiliated with professional and university sports teams throughout the United States. The first U.S. commercial surgery using the implant was performed in April. The Menaflex, which has been used for years in Europe, was cleared for U.S. marketing in December 2008.
“U.S. surgeons have shown a high interest in the Menaflex device,” said ReGen Chairman and CEO Gerald E. Bisbee Jr., Ph.D. “We are pleased to be conducting training in advance of the AANA annual meeting. The AANA’s surgeon members are highly trained arthroscopic specialists who will be among the first to appreciate the potential for treating meniscus injuries with this device.”
The surgeon training program provides guidance on insertion and use of the Menaflex device, as well as information concerning the role the device plays in meniscus preservation. The Menaflex procedure has been called an important new treatment option for patients that experience meniscus deficiency, and had been cited for its potential to decrease pain, improve function and decrease reoperation rates.
ReGen will host an exhibit at booth #520-522 throughout the AANA meeting.